{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T03:02:40Z","timestamp":1784343760141,"version":"3.55.0"},"reference-count":15,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T00:00:00Z","timestamp":1765929600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Farmacia Hospitalaria"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.farma.2025.12.005","type":"journal-article","created":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T12:13:54Z","timestamp":1770207234000},"page":"T158-T161","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["[Translated article] Alemtuzumab in relapsing\u2013remitting multiple sclerosis in clinical practice: Annual NEDA-3 follow-up for up to 4\u202fyears"],"prefix":"10.1016","volume":"50","author":[{"given":"Leticia","family":"Herrero-Poch","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Susana","family":"Fortes-Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Pato-Pato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo","family":"Gaveiras-Ara\u00fajo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mart\u00edn","family":"Lorenzo-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel Apolinar","family":"Garc\u00eda-Est\u00e9vez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose Ram\u00f3n","family":"Lorenzo-Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.farma.2025.12.005_bb0005","series-title":"Recomendaciones diagn\u00f3stico terap\u00e9uticas de la SEN 2023. Manual de pr\u00e1ctica cl\u00ednica en esclerosis m\u00faltiple, NMO y MOGAD","author":"Llaneza","year":"2023"},{"issue":"14","key":"10.1016\/j.farma.2025.12.005_bb0010","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1177\/13524585211003291","article-title":"Alemtuzumab treatment in Denmark: a national study based on the Danish Multiple Sclerosis Registry","volume":"27","author":"Theodorsdottir","year":"2021","journal-title":"Mult Scler"},{"issue":"6","key":"10.1016\/j.farma.2025.12.005_bb0015","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1007\/s00415-019-09272-6","article-title":"Efficacy and safety of alemtuzumab in a real-life cohort of patients with multiple sclerosis","volume":"266","author":"Frau","year":"2019","journal-title":"J Neurol"},{"issue":"10","key":"10.1016\/j.farma.2025.12.005_bb0020","doi-asserted-by":"crossref","first-page":"2440","DOI":"10.1007\/s00415-019-09424-8","article-title":"Outcomes after fingolimod to alemtuzumab treatment shift in relapsing\u2013remitting MS patients: a multicentre cohort study","volume":"266","author":"Frau","year":"2019","journal-title":"J Neurol"},{"issue":"12","key":"10.1016\/j.farma.2025.12.005_bb0025","doi-asserted-by":"crossref","first-page":"2851","DOI":"10.1007\/s00415-018-9070-x","article-title":"No evidence of disease activity (NEDA-3) and disability improvement after alemtuzumab treatment for multiple sclerosis: a 36-month real-world study","volume":"265","author":"Prosperini","year":"2018","journal-title":"J Neurol"},{"issue":"4","key":"10.1016\/j.farma.2025.12.005_bb0030","doi-asserted-by":"crossref","first-page":"259","DOI":"10.3233\/JRS-191029","article-title":"Alemtuzumab for relapsing multiple sclerosis in clinical practice: a four-year retrospective one-center study","volume":"31","author":"Rodr\u00edguez de Castro","year":"2020","journal-title":"Int J Risk Saf Med"},{"key":"10.1016\/j.farma.2025.12.005_bb0035","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s40263-024-01066-3","article-title":"Real-world retrospective analysis of alemtuzumab outcomes in relapsin-remitting multiple sclerosis: the LEMCAM study","volume":"38","author":"Costa-Frossard","year":"2024","journal-title":"CNS Drug"},{"issue":"11","key":"10.1016\/j.farma.2025.12.005_bb0040","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1212\/WNL.0000000000004313","article-title":"Alemtuzumab CARE-MS I 5-year follow-up: durable efficacy in the absence of continuous MS therapy","volume":"89","author":"Havrdova","year":"2017","journal-title":"Neurology"},{"issue":"11","key":"10.1016\/j.farma.2025.12.005_bb0045","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1212\/WNL.0000000000004354","article-title":"Alemtuzumab CARE-MS II 5-year follow-up: efficacy and safety findings","volume":"89","author":"Coles","year":"2017","journal-title":"Neurology"},{"issue":"9856","key":"10.1016\/j.farma.2025.12.005_bb0050","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/S0140-6736(12)61769-3","article-title":"Alemtuzumab versus interferon beta-1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial","volume":"380","author":"Cohen","year":"2012","journal-title":"Lancet"},{"issue":"9856","key":"10.1016\/j.farma.2025.12.005_bb0055","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1016\/S0140-6736(12)61768-1","article-title":"Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial","volume":"380","author":"Coles","year":"2012","journal-title":"Lancet"},{"issue":"17","key":"10.1016\/j.farma.2025.12.005_bb0060","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1056\/NEJMoa0802670","article-title":"Alemtuzumab vs. interferon beta-1a in early multiple sclerosis","volume":"359","author":"CAMMS223 Trial investigators","year":"2008","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.farma.2025.12.005_bb0065","doi-asserted-by":"crossref","first-page":"4591","DOI":"10.1007\/s10072-021-05145-x","article-title":"Effectiveness and safety of alemtuzumab in the treatment of active relapsing\u2013remitting multiple sclerosis: a multicenter, observational study","volume":"42","author":"Breel Jakob","year":"2021","journal-title":"Neurol Sci"},{"key":"10.1016\/j.farma.2025.12.005_bb0070","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/17562864231194823","article-title":"Safety and efficacy with alemtuzumab over 13 years in relapsing-remitting multiple sclerosis: final results from the open-label TOPAZ study","volume":"16","author":"Coles","year":"2023","journal-title":"Ther Adv Neurol Disord"},{"key":"10.1016\/j.farma.2025.12.005_bb0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2019.101504","article-title":"Alemtuzumab treatment of multiple sclerosis in real-world clinical practice: a report from a single Italian center","volume":"38","author":"Di Ioia","year":"2020","journal-title":"Mult Scler Relat Disord"}],"container-title":["Farmacia Hospitalaria"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1130634325001837?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1130634325001837?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T02:19:31Z","timestamp":1784341171000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1130634325001837"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":15,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S1130634325001837"],"URL":"https:\/\/doi.org\/10.1016\/j.farma.2025.12.005","relation":{},"ISSN":["1130-6343"],"issn-type":[{"value":"1130-6343","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"[Translated article] Alemtuzumab in relapsing\u2013remitting multiple sclerosis in clinical practice: Annual NEDA-3 follow-up for up to 4\u202fyears","name":"articletitle","label":"Article Title"},{"value":"Farmacia Hospitalaria","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.farma.2025.12.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.farma.2025.10.011","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Sociedad Espa\u00f1ola de Farmacia Hospitalaria (S.E.F.H). Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}]}}